Antigen Information

General Information of This Antigen (ID: TAR0GORST)
Antigen Name
Cytotoxic T-lymphocyte protein 4 (CTLA4)
Gene Name
CTLA4
Gene ID
1493
Synonym
CD152; Cytotoxic T-lymphocyte-associated antigen 4;CD152
Sequence
MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEY
ASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLR
AMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFL
LTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN

    Click to Show/Hide
Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.

    Click to Show/Hide
Uniprot Entry
CTLA4_HUMAN
HGNC ID
HGNC:2505
KEGG ID
hsa:1493
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Anti-CTLA4 mAb clone 9D9
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CTLA4-IR700 [1]
IRDye 700DX
Undisclosed
Undisclosed
 ADC Info 
Ipilimumab
 Antibody Info 
ADC Name Payload Target Linker ADC Info
Ipilimumab-Compound 9 [2]
Mertansine DM1
Microtubule (MT)
Ipilimumab-Compound 9 linker
 ADC Info 
Ipilimumab-Compound 17 [2]
Mertansine DM4
Microtubule (MT)
Ipilimumab-Compound 17 linker
 ADC Info 
Ipilimumab-Compound 25 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 25 linker
 ADC Info 
Ipilimumab-Compound 31 [2]
Auristatin 0101
Microtubule (MT)
Ipilimumab-Compound 31 linker
 ADC Info 
Ipilimumab-Compound 36 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 36 linker
 ADC Info 
Ipilimumab-Compound 43 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Ipilimumab-Compound 43 linker
 ADC Info 
Ipilimumab-Compound 49 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Ipilimumab-Compound 49 linker
 ADC Info 
Ipilimumab-Compound 55 [2]
Mertansine DM1
Microtubule (MT)
Ipilimumab-Compound 55 linker
 ADC Info 
Ipilimumab-Compound 59 [2]
Mertansine DM4
Microtubule (MT)
Ipilimumab-Compound 59 linker
 ADC Info 
Ipilimumab-Compound 64 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 64 linker
 ADC Info 
Ipilimumab-Compound 69 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 69 linker
 ADC Info 
Ipilimumab-Compound 74 [2]
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Ipilimumab-Compound 74 linker
 ADC Info 
Ipilimumab-Compound 75 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 75 linker
 ADC Info 
Ipilimumab-Compound 76 [2]
Monomethyl auristatin E
Microtubule (MT)
Ipilimumab-Compound 76 linker
 ADC Info 
Ipilimumab-Compound 77 [2]
Mertansine DM1
Microtubule (MT)
Ipilimumab-Compound 77 linker
 ADC Info 
Ipilimumab-Compound 78 [2]
Auristatin 0101
Microtubule (MT)
Ipilimumab-Compound 78 linker
 ADC Info 
Ipilimumab-Compound 79 [2]
Auristatin 0101
Microtubule (MT)
Ipilimumab-Compound 79 linker
 ADC Info 
Ipilimumab-Compound 80 [2]
Mertansine DM4
Microtubule (MT)
Ipilimumab-Compound 80 linker
 ADC Info 
Ipi-DM1 38127423 [3]
Mertansine DM1
Microtubule (MT)
Undisclosed
 ADC Info 
Ipi-DM1 36909522 [4]
Mertansine DM1
Microtubule (MT)
Undisclosed
 ADC Info 
Undisclosed
 Antibody Info 
ADC Name Payload Target Linker ADC Info
CTLA-4-targeted ETB [5]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
ADC CTLA4 Toxin [6]
Undisclosed
Undisclosed
Undisclosed
 ADC Info 
References
Ref 1 Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021 Nov;20(11):2262-2273. doi: 10.1158/1535-7163.MCT-21-0470. Epub 2021 Sep 13.
Ref 2 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 3 CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Ref 4 CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
Ref 5 Preclinical characterization of a novel CTLA-4-targeted ETB for direct Treg depletion. Cancer Res (2021) 81 (13_Supplement): 1627.
Ref 6 Introduction to basic information on anti CTLA4 antibody drug conjugate (Lanier Biotherapeutics).